SFM
BOLD

Sphera Funds Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Sphera Funds Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-120,000
Closed -$4.75M – 134
2018
Q3 		$4.75M Buy
+120,000
New +$4.47M 0.55% 51
2018
Q2 		– Sell
-95,000
Closed -$2.85M – 140
2018
Q1 		$2.85M Hold
95,000
– – 0.43% 65
2017
Q4 		$2.97M Hold
95,000
– – 0.35% 72
2017
Q3 		$2.66M Sell
95,000
-55,000
-37% -$1.19M 0.38% 68
2017
Q2 		$2.87M Buy
+150,000
New +$2.4M 0.49% 62
2016
Q4 		– Sell
-150,000
Closed -$2.67M – 130
2016
Q3 		$2.67M Buy
+150,000
New +$2.28M 0.44% 60

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Sphera Funds Management's BOLD Position: Q4 2018 in Review

Sphera Funds Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2018, closing a stake of 120,000 shares — an estimated $4.75M sold.

Sphera Funds Management first reported a position in BOLD in Q3 2016 and held it in 6 quarters. The position peaked at $4.75M in Q3 2018. 126 funds tracked by Wall St. Rank hold BOLD as of Q4 2018.

  • Sphera Funds Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Sphera Funds Management sold 120,000 Audentes Therapeutics, Inc shares in Q4 2018, an estimated $4.75M.
  • Sphera Funds Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 6 quarters.
  • Sphera Funds Management's Audentes Therapeutics, Inc position peaked at $4.75M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2018.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.